Nuclear medicine

ITM and Clovis Oncology Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Tuesday, October 19, 2021
Science, Radiology, Biotechnology, Research, Pharmaceutical, Oncology, Health, Clinical Trials, Peptide, Database administrator, EMA, Security (finance), Mesothelioma, Bone, ART, Patient, Radiopharmaceutical, Nuclear medicine, Safety, Drug discovery, Isotope, View, Private Securities Litigation Reform Act, Sarcoma, CAFS, Fibroblast, Leadership, Cancer, Population, Radionuclide, Cell, Antibody, Neoplasm, U.S. Securities and Exchange Commission, Lung, Colon, Breast cancer, Glioblastoma, FDA, Half-life, CEO, Trial of the century, FAP, NASDAQ, ITM, Wilms' tumor, TRT, Multimedia, Osteosarcoma, Program, Research, NCT, Radiation, Therapy, Clovis Oncology, Prostate cancer, Pharmaceutical industry, Medical imaging

ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.

Key Points: 
  • ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, and Clovis Oncology, Inc. (NASDAQ: CLVS) today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.
  • 177Lu), EndolucinBeta, for use in the clinical development of FAP-2286, Clovis fibroblast activation protein (FAP)-targeting therapeutic candidate.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement allows us to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.

Blue Earth Diagnostics Highlights Presentations on Axumin® (Fluciclovine F 18) and 18F-Fluciclovine at Upcoming ASTRO Annual Meeting

Retrieved on: 
Tuesday, October 19, 2021
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Acquisition, Anaphylaxis, Annual general meeting, Man, Magnetic resonance imaging, Cancer, Risk, ASTRO, Radiation therapy, Cardiac catheterization, Recurrence, Emory University, Dysgeusia, Department, Interventional radiology, MSEE, Nuclear medicine, Winship Cancer Institute, FDA, Google Images, PET, MRI, 3D ultrasound, Patient, CEUS, Radiation, Solution, Health, Molecular imaging, Exhibit, PSA, Magnetic resonance, Prostate cancer, Medical imaging, Vaccine

Blue Earth Diagnostics invites participants at the 2021 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 665.

Key Points: 
  • Blue Earth Diagnostics invites participants at the 2021 ASTRO Annual Meeting to attend the presentations above and visit the company at Exhibit Booth 665.
  • For full session details and scientific presentation listings, please see the ASTRO online program here .
  • Blue Earth Diagnostics expanding oncology portfolio encompasses a variety of disease states, including prostate cancer and neuro-oncology.
  • Blue Earth Diagnostics is committed to the timely development and commercialization of precision radiopharmaceuticals for potential use in imaging and therapy.

Clovis Oncology and ITM Announce Lutetium-177 Clinical Supply Agreement

Retrieved on: 
Tuesday, October 19, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, General Health, Health, Clinical Trials, Peptide, Database administrator, EMA, Security (finance), Mesothelioma, Bone, ART, Patient, Radiopharmaceutical, Nuclear medicine, Oncology, Safety, Drug discovery, Isotope, View, Private Securities Litigation Reform Act, Sarcoma, CAFS, Fibroblast, Clovis Oncology, Leadership, Cancer, Population, Radionuclide, Cell, Antibody, Neoplasm, U.S. Securities and Exchange Commission, Lung, Colon, Breast cancer, Glioblastoma, FDA, Half-life, CEO, Trial of the century, FAP, NASDAQ, ITM, Wilms' tumor, TRT, Osteosarcoma, Program, Research, NCT, Radiation, Therapy, Prostate cancer, Pharmaceutical industry, Medical imaging, FAP-2286, n.c.a. Lutetium-177 / EndolucinBeta®, Targeted Radionuclide Therapy, ITM Isotope Technologies Munich SE, Clovis Oncology, FAP-2286, N.C.A. LUTETIUM-177 / ENDOLUCINBETA®, TARGETED RADIONUCLIDE THERAPY, ITM ISOTOPE TECHNOLOGIES MUNICH SE, CLOVIS ONCOLOGY

Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.

Key Points: 
  • Clovis Oncology, Inc. (NASDAQ: CLVS) and ITM Isotope Technologies Munich SE , a leading radiopharmaceutical biotech company, today announced the signing of a clinical supply agreement that provides Clovis Oncology with ITMs therapeutic radioisotope no-carrier-added Lutetium-177 (n.c.a.
  • 177Lu), EndolucinBeta, for use in the clinical development of FAP-2286, Clovis fibroblast activation protein (FAP)-targeting therapeutic candidate.
  • Clovis Oncology is committed to advancing FAP-2286s clinical development program and emerging as a leader in targeted radionuclide therapy.
  • A critical element to advance this program is ensuring long-term supply of radioisotopes, and this agreement allows us to achieve that goal, said Patrick Mahaffy, President and CEO of Clovis Oncology.

Hitachi, Tohoku University and Kyoto University Become World's First to Establish Technology for Highly Efficient, High-quality Production of Actinium-225, a Material Required for Internal Radiation Therapy Called TAT

Retrieved on: 
Tuesday, October 19, 2021
Photon, Institute for Materials Research, Kyoto University, National university, Electronvolt, Association, Method, Adult, Tohoku University, Patient, Efficiency, Chemistry, Safety, Associate, Institute, Cancer, Appropriate Infrastructure Development Group, Electromagnetism, Security, Actinium-225, Nuclear medicine, KUR, Electromagnetic radiation, TAT, ELPH, European Association of Urology, KUCA, Uranium, Physics, Science, Continental Automotive Systems, Biology, Cell, Technology, Electron, Radium Girls, Medicine, Engineering, IMR, Thorium, TSE, Environment, Research institute, Radiation, Alpha, Plutonium, Quality of life, Research, Radium, Agriculture, Medical imaging, Pharmaceutical industry, Fine chemical, Fossil fuel, Microscope

Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).

Key Points: 
  • Hitachi, Tohoku University, and Kyoto University will continue research and development efforts to bring this production technology into commercial use, to help put TAT into clinical practice and ultimately improve cancer patients' quality of life (QoL).
  • Hitachi makes effort to pursue research and development that promotes the Security & Safety (healthy and comfortable life for each individual) of society.
  • External radiation uses beams of radiation delivered outside the body to target cancer cells, while internal radiation involves internal delivery of radiation.
  • Research Center for Electron Photon Science (ELPH), Tohoku University Hidetoshi Kikunaga, Associate Professor
    Institute for Integrated Radiation and Nuclear Science, Kyoto University

Global Cesium Market Outlook Report 2021-2026 Featuring Cabot Corp, American Elements, Avalon Advanced Materials, and Pioneer Resources - ResearchAndMarkets.com

Retrieved on: 
Monday, October 18, 2021
Chemicals, Plastics, Manufacturing, Avalon, Cabot Corporation, ASTRO, Caesium, 3D, Growth, Computer security, Prostate, Nuclear medicine, Efficiency, IsoRay, Brachytherapy, Pioneer Resources, PET, Seed, Communication, Radiosurgery, Medical imaging, Computer data storage

The global cesium market is expected to witness growth at a sluggish rate during the forecast period.

Key Points: 
  • The global cesium market is expected to witness growth at a sluggish rate during the forecast period.
  • The major factor responsible for the global cesium market's growth would be the increasing demand for cesium compounds in cancer treatment.
  • Other cesium compounds such as cesium carbonate, cesium hydroxide, and cesium bromide also have applications.
  • Major players in the market were found to be Cabot Corporation, American Elements, Avalon Advanced Materials, and Pioneer Resources, among others.

Bracco Celebrates Personalized and Precision Medicine Innovations at RSNA 2021

Retrieved on: 
Monday, October 18, 2021
MRI, Bracco (company), Research and development, Solution, Plant, Nuclear medicine, LinkedIn, Radiological Society of North America, Senior, RSNA, Precision medicine, Marketing, Compliance, Agent handling, Radiology, Magnetic resonance imaging, Google Images, FDA, Bracco, Patient, Food and Drug Administration, Annual general meeting, Food, Interventional radiology, Company, PET, 3D ultrasound, Informatics, Partnership, CEUS, Cardiac catheterization, R, Medical device, Medical imaging, Fine chemical

MONROE TOWNSHIP, N.J., Oct. 18, 2021 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announces diagnostic imaging, contrast media and informatics achievements that are propelling personalized and precision medicine forward while demonstrating understanding of the community's needs today.

Key Points: 
  • MONROE TOWNSHIP, N.J., Oct. 18, 2021 /PRNewswire/ -- Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., a leading global company in the diagnostic imaging business, today announces diagnostic imaging, contrast media and informatics achievements that are propelling personalized and precision medicine forward while demonstrating understanding of the community's needs today.
  • Innovations will be featured at the Bracco booth (#1129 South Hall Level 3) during the Radiological Society of North America (RSNA) Annual Meeting being held November 28 to December 2.
  • Bracco Imaging S.p.A., part of the Bracco Group, is a world-leading diagnostic imaging provider, headquartered in Milan, Italy.
  • Bracco Imaging has a strong presence in key geographies: North America, China, Europe, Japan, Brazil, Mexico and South Korea.

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Retrieved on: 
Monday, October 18, 2021
Leadership, Organization, Pleasure, TAT, Technology, Radiochemistry, Industry, Solution, National Nuclear Laboratory, Actinium-225, Antibody, Nuclear medicine, GMP, Marketing, Transport, BEI, DNA, Patient, GLOBE, Investment, Â, Radionuclide, CEO, ITM, Good manufacturing practice, Safety, Research, Memorandum of understanding, CNL, Medical imaging, Renewable energy

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

ITM and CNL Sign Memorandum of Understanding to Pursue Global Development and Production of Rare Medical Radioisotope, Actinium-225

Retrieved on: 
Monday, October 18, 2021
Research, Clinical Trials, Biotechnology, Radiology, Health, Pharmaceutical, Other Science, Science, Oncology, Leadership, Organization, Pleasure, Technology, TAT, Radiochemistry, Industry, Solution, National Nuclear Laboratory, Actinium-225, Antibody, Nuclear medicine, GMP, Transport, Marketing, DNA, Patient, Investment, Â, Radionuclide, CEO, ITM, Good manufacturing practice, Safety, Research, Memorandum of understanding, CNL, Medical imaging, Renewable energy, ITM Isotope Technologies Munich SE, CNL, ITM ISOTOPE TECHNOLOGIES MUNICH SE, CNL

Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.

Key Points: 
  • Under the terms of the agreement, the organizations will collaborate on the development, manufacturing, and distribution pathways for the medical radioisotope.
  • ITM is a world leader in the development, production and global supply of radiotherapeutics and diagnostics, and maintains an evolving precision oncology pipeline.
  • Under the terms of the agreement, CNL will be responsible for the research and development as well as the production of Actinium-225.
  • CNL and ITM aim to leverage their capabilities towards establishing a continuous commercial supply of GMP-grade Actinium-225 for the global market.

First Cyclotron Removed from Seneffe Production Facility by SCK CEN

Retrieved on: 
Monday, October 18, 2021
General manager, Australian Securities Exchange, Industry, Publication, Environment, LinkedIn, ASX, SCK, Cancer, TGA, Employment, CEN, Degenerative disease, SCK CEN, Nuclear medicine, Cyclotron, MTR, Australian Radiation Protection and Nuclear Safety Agency, News, Patient, GLOBE, Economic development, Radioactive decay, Safety, TLX, Research, Partnership, AFCN, Saclay Nuclear Research Centre, Fine chemical

The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.

Key Points: 
  • The cyclotron weighing approximately 22 tonnes was successfully removed by SCK CEN, a leader in nuclear safety and facility decommissioning.
  • Once the second cyclotron has been removed later this year, Telix will be able to formally commence the build-out of a new state-of-the-art facility for medical radioisotope production and drug product manufacturing.
  • The sooner Telix can start production, the sooner these important products can reach cancer patients," stated Michel Estas, decommissioning expert at SCK CEN.
  • Sbastien Linard de Guertechin, General Manager of the Seneffe Facility stated, Telix is delighted to be working with SCK CEN for the decommissioning.

Kathleen Harper, DO, FACC, FACP is recognized by Continental Who's Who

Retrieved on: 
Thursday, October 14, 2021
American Osteopathic Association, FACP, Degenerative disease, Internship, American Board of Internal Medicine, American College, Nuclear medicine, Continental, American College of Cardiology, Woman, Internal medicine, FACC, Medical Center, Osteopathic medicine in the United States, Multimedia, University of New England College of Osteopathic Medicine, Sgt. Pepper's Lonely Hearts Club Band (film), American Society of Nuclear Cardiology, Fellow, Patient, Health, Integrating the Healthcare Enterprise, American Board of Commissioners for Foreign Missions, Baystate Health, American College of Physicians, Society, University, Medical degree, St. Vincent's, Alternative, Saint Vincent, Togus, Maine, St. Vincent's Hospital, DO, Heart failure, American Society of Echocardiography, Hospital, Medical imaging

She is currently serving a leadership role at Togus VA Medical Center in Maine as the Chief of Cardiology and demonstrating the highest level of medical excellence.

Key Points: 
  • She is currently serving a leadership role at Togus VA Medical Center in Maine as the Chief of Cardiology and demonstrating the highest level of medical excellence.
  • In this capacity, she taught patients how to lead a healthy lifestyle and promotes the prevention of heart disease and other problems.
  • She went on to complete her Internship at Humana Hospital, her Residency at St. Vincent's Medical Center, and her Fellowship at University St. Vincent's Medical Center.
  • With a commitment to excellence, Dr. Harper is a distinguished Fellow of the American College of Cardiology (FACC) and the American College of Physicians (FACP).